6.
Puram S, Tirosh I, Parikh A, Patel A, Yizhak K, Gillespie S
. Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer. Cell. 2017; 171(7):1611-1624.e24.
PMC: 5878932.
DOI: 10.1016/j.cell.2017.10.044.
View
7.
Hong X, Yu J
. MicroRNA-150 suppresses epithelial-mesenchymal transition, invasion, and metastasis in prostate cancer through the TRPM4-mediated β-catenin signaling pathway. Am J Physiol Cell Physiol. 2018; 316(4):C463-C480.
DOI: 10.1152/ajpcell.00142.2018.
View
8.
Lu W, Zhang H, Niu Y, Wu Y, Sun W, Li H
. Long non-coding RNA linc00673 regulated non-small cell lung cancer proliferation, migration, invasion and epithelial mesenchymal transition by sponging miR-150-5p. Mol Cancer. 2017; 16(1):118.
PMC: 5504775.
DOI: 10.1186/s12943-017-0685-9.
View
9.
. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396(10258):1204-1222.
PMC: 7567026.
DOI: 10.1016/S0140-6736(20)30925-9.
View
10.
Kim S, Park S, Oh J, Lee S, Lee Y, Choi J
. MicroRNA-18a regulates the metastatic properties of oral squamous cell carcinoma cells via HIF-1α expression. BMC Oral Health. 2022; 22(1):378.
PMC: 9442921.
DOI: 10.1186/s12903-022-02425-6.
View
11.
Sawai S, Wong P, Ramasamy T
. Hypoxia-regulated microRNAs: the molecular drivers of tumor progression. Crit Rev Biochem Mol Biol. 2022; 57(4):351-376.
DOI: 10.1080/10409238.2022.2088684.
View
12.
Jin H, Jin X, Chai W, Yin Z, Li Y, Dong F
. Long non-coding RNA MIAT competitively binds miR-150-5p to regulate ZEB1 expression in osteosarcoma. Oncol Lett. 2019; 17(1):1229-1236.
PMC: 6312950.
DOI: 10.3892/ol.2018.9671.
View
13.
Hapke R, Haake S
. Hypoxia-induced epithelial to mesenchymal transition in cancer. Cancer Lett. 2020; 487:10-20.
PMC: 7336507.
DOI: 10.1016/j.canlet.2020.05.012.
View
14.
Zhao C, Popel A
. Computational Model of MicroRNA Control of HIF-VEGF Pathway: Insights into the Pathophysiology of Ischemic Vascular Disease and Cancer. PLoS Comput Biol. 2015; 11(11):e1004612.
PMC: 4654485.
DOI: 10.1371/journal.pcbi.1004612.
View
15.
Biyani C, Campain N, Moore M, Gobezie A, Teferi G, MacDonagh R
. Urolink supporting the development of urological services in Hawassa, Ethiopia. BJU Int. 2019; 123(6):917-920.
DOI: 10.1111/bju.14670.
View
16.
Ribatti D, Tamma R, Annese T
. Epithelial-Mesenchymal Transition in Cancer: A Historical Overview. Transl Oncol. 2020; 13(6):100773.
PMC: 7182759.
DOI: 10.1016/j.tranon.2020.100773.
View
17.
Luond F, Sugiyama N, Bill R, Bornes L, Hager C, Tang F
. Distinct contributions of partial and full EMT to breast cancer malignancy. Dev Cell. 2021; 56(23):3203-3221.e11.
DOI: 10.1016/j.devcel.2021.11.006.
View
18.
Vaira V, Faversani A, Dohi T, Maggioni M, Nosotti M, Tosi D
. Aberrant overexpression of the cell polarity module scribble in human cancer. Am J Pathol. 2011; 178(6):2478-83.
PMC: 3124121.
DOI: 10.1016/j.ajpath.2011.02.028.
View
19.
George J, Jolly M, Xu S, Somarelli J, Levine H
. Survival Outcomes in Cancer Patients Predicted by a Partial EMT Gene Expression Scoring Metric. Cancer Res. 2017; 77(22):6415-6428.
PMC: 5690883.
DOI: 10.1158/0008-5472.CAN-16-3521.
View
20.
Creane M, Howard L, OBrien T, Coleman C
. Biodistribution and retention of locally administered human mesenchymal stromal cells: Quantitative polymerase chain reaction-based detection of human DNA in murine organs. Cytotherapy. 2017; 19(3):384-394.
DOI: 10.1016/j.jcyt.2016.12.003.
View